- Home
- SRG vs CNTB Comparison
SRG vs CNTB Comparison
Compare SRG & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRG | CNTB |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.4M | 135.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SRG | CNTB |
|---|---|---|
| Price | $2.56 | $2.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 173.6K | ★ 677.5K |
| Earning Date | 05-14-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.31 | $1.23 |
| 52 Week High | $4.56 | $3.82 |
Technical Indicators
Market Signals| Indicator | SRG | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 45.93 |
| Support Level | $2.43 | $2.14 |
| Resistance Level | $2.74 | $2.75 |
| Average True Range (ATR) | 0.09 | 0.23 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 16.28 | 7.25 |
Price Performance
Historical ComparisonAbout SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties throughout the United States.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.